Alpha Centric Advisors LLC Cogent Biosciences, Inc. Transaction History

Alpha Centric Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$9.39 - $16.99 $352,125 - $637,124	-37,500 Closed	0 $0
Q4 2021 Feb 25, 2022	SELL	$7.51 - $10.81 $728,282 - $1.05 Million	-96,975 Reduced 72.11%	37,500 $322,000
Q3 2021 Mar 09, 2022	BUY	$5.99 - $9.14 $71,730 - $109,451	11,975 Added 9.78%	134,475 $1.13 Million
Q2 2021 Mar 09, 2022	BUY	$7.82 - $9.3 $254,150 - $302,250	32,500 Added 36.11%	122,500 $993,000
Q1 2021 Mar 09, 2022	BUY	$7.47 - $12.34 $525,141 - $867,502	70,300 Added 356.85%	90,000 $790,000
Q4 2020 Mar 11, 2022	BUY	$9.04 - $13.01 $178,087 - $256,297	19,700 New	19,700 $221,000

172

113M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $517M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.